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Abstract
Background: Arachidonic acid is metabolized through three major metabolic pathways, the cyclooxygenase, lipoxygenase
and CYP450 enzyme systems. Unlike cyclooxygenase and lipoxygenases, the role of CYP450 epoxygenases in monocyte/
macrophage-mediated responses is not known.
Methodology/Principal Findings: When transfected in vitro, CYP2J2 is an efficient activator of anti-inflammatory pathways
through the nuclear receptor peroxisome proliferator-activated receptor (PPAR) a. Human monocytes and macrophages
contain PPARa and here we show they express the epoxygenases CYP2J2 and CYP2C8. Inhibition of constitutive monocyte
epoxygenases using the epoxygenase inhibitor SKF525A induces cyclooxygenase (COX)-2 expression and activity, and the
release of TNFa, and can be reversed by either add back of the endogenous epoxygenase products and PPARa ligand 11,12-
epoxyeicosatrienoic acid (EET) or the addition of the selective synthetic PPARa ligand GW7647. In alternatively activated (IL-
4-treated) monocytes, in contrast to classically activated cells, epoxygenase inhibition decreased TNFa release.
Epoxygenases can be pro-inflammatory via superoxide anion production. The suppression of TNFa by SKF525A in the
presence of IL-4 was associated with a reduction in superoxide anion generation and reproduced by the superoxide
dismutase MnCl2. Similar to these acute activation studies, in monocyte derived macrophages, epoxygenase inhibition
elevates M1 macrophage TNFa mRNA and further decreases M2 macrophage TNFa.
Conclusions/Significance: In conclusion, epoxygenase activity represents an important endogenous pathway which limits
monocyte activation. Moreover endogenous epoxygenases are immuno-modulators regulating monocyte/macrophage
activation depending on the underlying activation state.
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Introduction
Monocyte-derived macrophages play a critical role in host defence,
wound healing, repair and chronic inflammation [1]. Depending on
the stimuli monocytes can be differentiated to either a classically
activated pro-inflammatory M1 macrophage (e.g. by IFNc,T N F a or
bacterial LPS) or an alternatively activated M2 macrophage (M2; e.g.
by IL-4 or IL-13) which in general are associated with Th2 mediated
immune responses, promote the killing of parasites, and are present
during tissue repair, wound healing and remodelling [1].
Arachidonic acid is metabolised in to families of biologically
active mediators by cyclooxygenase (COX), lipoxygenase and
CYP450 pathways [2,3]. Unlike COX and lipoxygenase products,
the roles of CYP450 pathways in the immune response are poorly
understood. CYPs metabolise arachidonic acid by: i) epoxygenases
that catalyze arachidonic acid to epoxyeicosatrienoic acids (EETs);
ii) the lipoxygenase-like CYPs; and iii) the v- and v-1-hydroxylase
CYPs which produce hydroxyeicosatetraenoic acids.[3] These
CYP-lipid metabolizing enzymes are the primary sources of
eicosanoids in small blood vessels, the kidney, liver, lung,
intestines, heart, and pancreas [3,4]. The main arachidonic acid-
metabolising CYPs are members of the CYP2 family. Of this
larger family, the CYP2J and CYP2C sub families represent the
most important epoxygenases [3,4,5,6].
EETs can regulate vascular tone, smooth muscle cell mitogen-
esis, platelet aggregation, steroidogenesis and vascular inflamma-
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26591tion [4,6,7]. EETs have been hypothesized as endothelium-derived
hyperpolarizing factors, hyperpolarizing and relaxing vascular
smooth muscle cells by activating calcium-activated potassium
channels [5]. A number of the anti-inflammatory activities of
EETs and CYP2J2 in particular are independent of hyperpolar-
isation [8]. CYP2C9 increases NFkB activity in human vascular
endothelium [9], giving CYP2C9 a potential pro-inflammatory
profile. Indeed, in general, CYP2Cs have a propensity to uncouple
and produce reactive oxygen species whereas CYP2J isoforms do
not. The receptors for epoxygenase products are poorly under-
stood. We recently published that CYP2J2 and its anti-inflamma-
tory products are ligands for the peroxisome-proliferator activated
receptor (PPAR) class of nuclear receptors, in particular PPARa
[10]. PPARa is expressed in the vascular endothelium, vascular
smooth muscle cells, and monocyte/macrophages where, like
EETs, it can limit NFkB activation [11].
Over the last 10 years it has been recognized that endothelial
cells contain epoxygenases (in man CYP2J2, CYP2C8 and
CYP2C9), which regulate endothelial cell adhesion molecule
expression and inflammatory cell recruitment [4]. CYP2J2 in
particular has a number of vascular protective properties including
protection of hypoxia-reoxygenation endothelial injury [12],
decreased cytokine-induced cell adhesion molecule expression by
inhibition of NFkB [8], reduction of inflammatory cell recruitment
[13], and the reduction of hypertension and hypertension induced-
renal injury [14] and smooth muscle migration [15]. In contrast,
the expression and function of epoxygenases in monocytes is
poorly understood, even though it is known epoxygenase products
are produced by human macrophages [16] and bind to sites in
monocytes [17]. Our aims were to examine whether epoxygenases
played a immuno-modulatory role in monocyte macrophage
activity. We show endogenous epoxygenase activity limits
monocyte/macrophage activation when stimulated either in a
classical pro-inflammatory manner or with alternative activation.
Endogenous epoxygenases are therefore important immuno-
modulators regulating monocyte/macrophage activation depend-
ing on the manner of their activation.
Results
Transfected CYP2J2 activates anti-inflammatory
pathways through PPARa
We have recently shown that CYP2J2 and its products 8,9-EET
and 11,12-EET activate PPARa in vitro in HEK293 cells, and that
CYP2J2 augments PPARa signaling in vivo in the heart [10]. Here
we show CYP2J2 and PPARa co-transfection abolishes IL-1b
induced NFkB reporter gene activation (Figure 1A), or IL-1b and
PMA-induced COX-2 mRNA induction (Figure 1B) in HEK293
cells. Transfection with either CYP2J2 or PPARa reduced IL-1b-
induced NFkB activation, but both were required to abolish the
response (Cont 1.560.3; IL-1b 5.660.7; IL-1b+CYP2J2 3.360.5;
IL-1b+PPARa 3.360.4; IL-1b+CYP2J2+PPARa 1.560.2 fold
NFkB activation; CYP2J2 1.360.1 or PPARa 1.060.1 transfected
by themselves did not affect basal NFkB activation). The anti-
inflammatory effect of the combination of CYP2J2 activity and
PPARa activation could be reversed by either CYP2J2 inhibition
with 30 mM SKF525A (Figure 1A and 1B), PPARa inhibition by
the PPARa antagonist GW6471 (1 mM) or the presence of co-
transfected dominant-negative PPARa (Figure 1A). We previously
showed that SKF525A up to concentrations of 30 mM produced a
concentration-dependent inhibition of CYP2J2 induced PPAR
reporter gene activation [10]. In longer-term experiments however
(.24 h), 30 mM SKF525A reduced cell viability (assessed by MTT
assay), so 10 mM SKF525A, which had no significant effect on cell
viability under any of the conditions tested (data not shown) was
used in all the subsequent experiments.
The addition of the known products of CYP2J2, 8,9-EET or
11,12-EET (1 mM) strongly inhibited IL-1b-induced NFkB
reporter gene activity in the absence of PPARa (Figure 2). In
the presence of transfected PPARa,N F kB activity was abolished
using either 8,9-EET or 11,12-EET indicating that EETs may
have anti-inflammatory actions both dependent and independent
of PPARa (Figure 2).
Epoxygenase activity in monocytes constitutively limits
inflammatory activation in a manner sensitive to PPARa
ligands
CYP2J2 and CYP2C8 (but not CYP2C9) were expressed in
human THP-1 monocytes and human peripheral blood mono-
cytes (Figure 3). THP-1 cells produced low levels of the stable
epoxygenase products of arachidonic acid: 8,9-EET (8,9-DHET;
Figure 1. CYP2J2 has anti-inflammatory actions in vitro
through the activation of PPARa. (A) CYP2J2 and PPARa co-
transfection abolishes IL-1b (10 ng/ml; 18 h) induced NFkB reporter
gene activation. HEK293 cells were transfected with a NFkB-luciferase
reporter gene and combinations of expression plasmids for CYP2J2 and
PPARa, or control empty plasmid (pcDNA3.1). The CYP2J2-PPARa
mediated inhibition of IL-1b-induced NFkB activation is reversed by
SKF525A (30 mM), co-transfection with dominant negative (DN)-PPARa,
or a selective PPARa antagonist GW6471 (3 mM). *denotes p,0.05
between IL-1b and treatments, by one-way ANOVA and Bonferroni’s
post test. Data represents mean6SEM of n=9 determinations from 3
separate experiments. (B) CYP2J2 and PPARa co-transfection abolishes
IL-1b (10 ng/ml) and PMA (1 nM) induced COX-2 mRNA expression
(24 h) determined by semi-quantitative RT-PCR. The abolishment of
COX-2 mRNA is reversed when cells are co-incubated with the
epoxygenase inhibitor SKF525A (30 mM). *denotes p,0.05 between
IL-1b + PMA induced COX-2 expression and the effect of treatments by
one-way ANOVA and Bonferroni’s post-test. Data represents mean 6
SEM of n=9 determinations from 3 separate experiments.
doi:10.1371/journal.pone.0026591.g001
Monocyte/Macrophage Epoxygenases
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e265912.060.3 pg/ml), and linoliec acid, 9,10-epoxy-octadecenoic acid
(EPOME) (9,10-dihydroxy-octadecenoic acid, 213.56111.8 pg/
ml) over 24 h. CYP2J2, CYP2C8 or CYP2C9 transcripts were not
detected in human PMNs (Figure 3A). Classical activation of
monocytes with IL-1b and PMA induced COX-2 protein in a
manner sensitive to inhibition by either the epoxygenase product
11,12-EET or the selective PPARa ligand GW7647 [18]
(Figure 4A and B). IL-1b alone in both HEK293 or THP-1 cells
was insufficient to reproducibly induce COX-2, however the
combination of IL-1b with PMA gave a consistent reproducible
induction of both COX-2 mRNA and protein. Surprisingly, in the
absence of additional stimuli, epoxygenase inhibition using SKF525A
alone greatly induced COX-2 protein in THP-1 (Figure 4C and D),
which could be reversed by PPARa activation. Similarly, SKF525A
induced PGD2 release (Figure 4E) and TNFa release (Figure 4G). In
addition, the selective PPARa antagonist GW6471 (10 mM) induced
PGD2 and TNFa release (Figure 4E and 4G), or the cPLA2 inhibitor
AACOCF3 (30 mM; Figure 4G) induced TNFa release similar to
SKF525A. The cPLA2 inhibitor was not tested for PGD2 release as it
would directly inhibit PGD2 synthesis independent of any effect on
EET generation. Although, the level of COX-2 protein induced by
epoxygenase inhibition was similar to IL-1b and PMA stimulation,
the level of PGD2 released were significantly greater with IL-1b and
PMA stimulation (Figure 4F). In addition to inflammatory pathways,
epoxygenase inhibition also increased the uptake of Dil-labeled
acetylated-LDL in a manner sensitive to inhibition with GW7647
(Figure S1). In THP-1 cells, no uptake was observed until the
monocytes had been activated with 1 nM PMA for 24 h, before
treatment with SKF525A.
Epoxygenase activity differentially regulates alternatively
activated monocytes and macrophages
THP-1 monocytes treated with the alternative activator of
monocytes IL-4 (20 ng/ml) exhibited a small reduction in TNFa
release over 7 h (Figure 5A). In cells treated with IL-4 and the
epoxygenase inhibitor SKF525A (10 mM), TNFa release was
further reduced (Figure 5), suggesting that epoxygenases are
immuno-modulators depending on the underlying activation state
of the monocyte. Similar results were found for COX-2 (and TNFa)
mRNA levels (Figure S2A and B). Under basal cell culture
conditions 11,12-EET and 8,9-EET strongly inhibited TNFa
release. In contrast, in the presence of IL-4 and SKF525A, although
11,12-EET retained its inhibitory activity, 8,9-EET elevated TNFa
levels (Figure 5B), suggesting a shift in the cells ability to sense this
anti-inflammatory EET. A change in the sensitivity to an anti-
inflammatory EET may therefore help to explain this pro-
inflammatory action of IL-4 under these conditions.
Moreover, since epoxygenases can activate pro-inflammatory
pathways via superoxide generation [9], we monitored superoxide
generation and compared SKF525A responses to that of the
superoxide dismutase compound MnCl2 [19]. MnCl2 (10 mM)
identical to epoxygenase inhibition decreased TNFa release in the
presence but not absence of IL-4 (Figure 5A), showing that
superoxide anion generation from epoxygenases can account for
the reduction in TNFa release under conditions of alternative
activation. Superoxide generation was increased in both IL-4
(20 ng/ml) and SKF525 (10 mM) treated cells, the combination of
IL-4 with SKF525 however showed no significant increase of
superoxide generation over control treated cells (Figure 5C).
We differentiated human peripheral blood monocytes in to M1
and M2 macrophages with LPS (1 ng/ml) and IFNc (20 ng/ml),
or with IL-4 respectively, in the presence or absence of SKF525A
(10 mM) for 7 days (Figure 6). M1 macrophages were character-
ized by high transcript levels of COX-2 and TNFa, and low levels
of DC-SIGN (Figure 6A), in contrast M2 macrophages showed no
COX-2 expression, lower levels of TNFa, but high levels of the
M2 marker DC-SIGN (Figure 6A). M1 and M2 macrophages
expressed CYP2J2 and CYP2C8 mRNA. In addition, CYP2C9
Figure 2. Epoxygenase products inhibit NFkB activation
through PPARa-dependent manner and independent path-
ways. Exogenous EETs inhibit IL-1b-induced NFkB independently of
PPARa, HEK293 cells were transfected with a NFkB-luciferase reporter
gene with either an expression plasmid for PPARa, or control empty
plasmid (pcDNA3.1). 8,9-EET and 11,12-EET (1 mM) inhibit IL-1b induced
NFkB reporter gene in the presence and absence of co-transfected
PPARa. *denotes p,0.05 between IL-1b and treatments, by one-way
ANOVA and Bonferroni’s post test. Data represents mean 6 SEM of
n=9 determinations from 3 separate experiments.
doi:10.1371/journal.pone.0026591.g002
Figure 3. Human monocytes contain epoxygenases CYP2J2
and CYP2C8. (A) CYP2J2 and CYP2C8 mRNA determined by RT-PCR
are expressed in human peripheral leukocytes (Lk), monocytes (Mc) and
the THP-1 cell line, but not polymorphonuclear cells (PMNs).
Confirmation of CYP2J2 protein in human monocytes and THP-1 cells
was performed by western blotting. (B) HEK293 cells transfected with
empty vector (-) compared to HEK293 cells transfected with expression
plasmid for CYP2J2 (+) was used as a positive control. (C) CYP2J2
protein in human THP-1 cells and monocytes (Mc). Figures are
representative of n=324 independent experiments.
doi:10.1371/journal.pone.0026591.g003
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(Figure 6B). In experiments where SKF525A was included during
the differentiation process, identical to our findings in monocytes,
M1 macrophages had increased TNFa mRNA (Figure 6C and D),
while M2 macrophages had significantly reduced TNFa mRNA
levels (Figure 6E and 6F). TNFa release by ELISA could not be
accurately measured in M1 and M2 macrophages due to low and
variable cell numbers. We therefore measured TNFa release in
THP-1 cells treated with M1 and M2 differentiation medium for 7
days. In these experiments, SKF525A treatment was only given for
a 7 h period at the end of the experiment and not throughout.
SKF525A did not affect the release of TNFa in M1-THP-1 cells
(Figure 6D), but greatly reduced the release of TNFa by M2-THP-
1 cells (Figure 6F). The absolute levels of TNFa release were less in
M1 compared to M2-THP-1 cells due to a large reduction in cell
viability with the M1 differentiation conditions. SKF525A at this
7 h time point did not however effect cell viability in either M1 or
M2 differentiated cells.
Discussion
The roles of epoxygenase pathways in monocytes and
macrophages remain poorly understood. Here we show endoge-
nous epoxygenases provide a critical endogenous break on
monocyte/macrophage cell inflammatory pathway activation
under resting conditions and when activated to differentiate to
the M1 phenotype. We choose to use the non-specific epoxygenase
inhibitor SKF525A as there are at least 2 epoxygenases present
and we wanted to ensure we had a complete inhibition of these
epoxygenases. PPARa, CYP2J2 and EETs have all been shown
independently to have anti-inflammatory properties, at least in
part by inhibition of NFkB. Consistent with our previous findings
that co-transfected CYP2J2 inhibited NFkB through providing
ligands for PPARa [20], here we show that the NFkB downstream
inflammatory targets COX-2 and TNFa are similarly regulated.
Epoxygenase products, which we previously showed capable of
activating PPARa [10], inhibited NFkB activation in the absence
Figure 4. Epoxygenase inhibition induces pro-inflammatory signals in human and murine monocytes in vitro. (A and B) COX-2 protein
induced in THP-1 cells by a combination of IL-1b (10 ng/ml) and PMA (1 nM) for 24 h is inhibited by co-incubation with either (A) 11,12-EET (1 mM) or
(B) the selective PPARa ligand GW7647 (10 nM). b-actin was measured to ensure equal loading of proteins. Data is representative of n=3 separate
experiments. (C and D) Epoxygenase blockade alone is sufficient to induce COX-2 in THP-1 monocytes. (C) SKF525A 0.1–10 mM gives a concentration-
dependent induction of COX-2 protein. Data is representative of n=4 separate experiments. (D) Epoxygenase blockade induces COX-2 in THP-1 cells
which is reversed by the selective PPARa agonist GW7647 (10 nM). Compared to the established pro-inflammatory combination of IL-1b and PMA
(used at optimal concentrations for COX-2 induction), SKF525A gives a robust induction of COX-2. Data represents mean 6 SEM of n=4 separate
experiments. *denotes p,0.05, by one-sample t-test treatments compared to untreated cells. (E) The COX derived prostanoid PGD2 is also induced in
THP-1 cells by epoxygenase (SKF525A 10 mM) or PPARa blockade (GW6471 10 mM) or (F) a combination of IL-1b (10 ng/ml) and PMA (1 nM) for 24 h.
(G) Similarly, TNFa is induced in THP-1 cells by epoxygenase (SKF525A 10 mM), PPARa blockade (GW6471 10 mM) or cPLA2 (AACOCF3 30 mM)
inhibition over 24 h. *denotes p,0.05 by Wilcoxon signed rank test treatments compared to untreated cells.
doi:10.1371/journal.pone.0026591.g004
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EETs was complete when PPARa was present, since our HEK293
cells do not contain any significant level of basal PPAR activity
[10], these results suggest that anti-inflammatory EETs can act
through both PPAR-dependent and PPAR-independent pathways.
Recently epoxygenases and their products were shown to regulate
inflammation at the level of the endothelial cell neutrophil
interactions [13]. Although PPARc has also been suggested as
an anti-inflammatory target for endothelial epoxygenases [21,22],
the reduction of pro-inflammatory cytokines induced by epox-
ygenases were reversed by the putative EET antagonist 14,15-
EEZE [13]. It must be noted however that 14,15-EEZE does not
have pure antagonist properties [23], and has yet to be tested on
the regulation of PPAR responses. One additional potential anti-
inflammatory mechanism for EETs is via cAMP generation. This
does not appear to be the case here as SKF525A had no affect on
cAMP levels in THP-1 cells, at least after 7 h of treatment (Fig
S2C).
Monocytes and macrophages contain PPARa [24] and here we
show they express CYP2J2 and CYP2C8, and release low levels of
epoxygenase products of arachidonic acid, and linoleic acid.
Interestingly, the stable levels of EETs release were much lower
than the levels of the linoleic acid product 9,10-EPOME. As yet
we don’t understand the importance of these alternative
epoxygenase fatty acid products in monocytes, but in our hands
9,10-EPOME does not have anti-inflammatory properties similar
to 11,12-EET as it does not inhibit basal TNFa release from THP-
1 cells (Fig S2D). PPARa knockout monocyte/macrophages exist
in a highly inflammatory state producing large amounts of
thrombospondin-1 and inhibiting tumor growth [25]. Inhibition
of monocyte epoxygenases using SKF525A strongly induced the
NFkB target genes COX-2 and TNFa, consistent with our in vitro
co-transfection studies. Indeed, inhibition of either epoxygenases,
or PPARa using the selective antagonist GW6471 induced
prostanoid release, or along with a cPLA2 inhibitor AACOCF3,
induced TNFa release to a similar extent, indicating that
inhibiting any of the components of a proposed pathway: cPLA2
- arachidonic acid - epoxygenase - EET - PPARa, results in a
similar monocyte activation. The increased expression of COX-2
was sensitive to inhibition by 11,12-EET (the EET we previously
described with the greatest potency to activate PPARa) or the
highly selective PPARa ligand GW7647 [18]. These results show
that epoxygenases supply a continuous anti-inflammatory tone in
monocytes at least in part by producing PPARa ligands.
It has been recently reported that CYP2J2 was absent in human
leukocytes, but present at high levels in malignant hematological
(lymphocytic) cell lines and in leukemia cells from peripheral blood
and bone marrow in patients with malignant hematologic diseases
[26]. Although we found CYP2J2 and CYP2C8 mRNA in human
total leukocytes, lymphocyte and monocyte fractions (but not
PMNs), the levels of mRNA were consistently lower than those
found in our THP-1 cells (a human acute monocytic leukemia cell
Figure 5. Epoxygenase inhibition in alternatively activated monocytes inhibits TNFa release: a role for superoxide generation. (A)
shows the acute release of TNFa from THP-1 cells over 7 h with vehicle treatment (Cont), or treated with SKF525A (10 mM), IL-4 (20 ng/ml), the
superoxide dismutase, MnCl2 (10 mM) or a combination of IL-4 and SKF525A or IL-4 and MnCL2. (B) shows inhibition of basal TNFa release from THP-1
cells treated with 11,12-EET or 8,9-EET (1 mM) in the presence of absence of SKF (10 mM) with IL-4 (20 ng/ml). Data represents mean 6 SEM of n=3
experiments. * indicates EET difference from control, while { indicates EET difference from IL-4 with SKF525A. (C) shows the production of superoxide
(left figure; arbitrary units), or representative florescent micrographs (right panels), from THP-1 cells treated for 7 h with vehicle treatment (Cont),
SKF525A (10 mM), IL-4 (20 ng/ml), or a combination of IL-4 and SKF525A. The superoxide sensor, dihydroethidium (10 mM) was added for the last
30 min and staining intensity analyzed using a Nikon TE2000 inverted florescent microscope connected to a SPOT-RT digital camera. Data represents
mean 6 SEM of n=324 experiments. *denotes p,0.05, by one-way ANOVA and Bonferroni’s post-test compared to control cells.
doi:10.1371/journal.pone.0026591.g005
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explain some of the poor immunological function of these cells,
and may point to the presence of a high degree of continuous
immuno-suppression through this pathway.
In contrast, when alternatively activated by IL-4, concurrent
epoxygenase inhibition instead of elevating TNFa suppressed
TNFa release and TNFa mRNA expression in THP-1 monocytes
or M2 macrophages respectively. Similar results were found with
COX-2 in THP-1 monocytes: however, there was no basal level of
COX-2 in M2 macrophages to modulate. These results show that
under alternative activation, epoxygenases have a pro-inflamma-
tory activity. Interestingly, IL-4 with SKF525A changed the
actions of the epoxygenase product 8,9-EET when given
exogenously. Under basal conditions 8,9-EET inhibited TNFa
release, while in the presence of IL-4 and SKF525A it elevated
TNFa levels. These intriguing results point to a new pro-
inflammatory EET pathway in monocytes sensitized by IL-4
which is specific to 8,9-EET, as 11,12-EET was unaffected. The
Figure 6. Epoxygenase inhibition differentially regulates the release of TNFa from M1 and M2 macrophages. (A) Differentiation of
human peripheral blood mononuclear cells for 7d with either LPS (1 ng/ml) and IFNc (20 ng/ml; M1) or IL-4 (20 ng/ml; M2) induces a characteristic
pattern of M1 (high COX-2, high TNFa, low DC-SIGN) and M2 (low COX-2, low TNFa and high DC-SIGN) macrophage differentiation. Markers were
measured by RT-PCR compared to b-actin. (B) CYP2J2 and CYP2C8 mRNA are expressed in M1 and M2 macrophages. In addition CYP2C9 is expressed
in (2 out of 4) macrophages. Blots are representative of n=4 independent experiments. (C-F) TNFa mRNA (top) and protein (lower panels) is
differentially regulated in M1 (C and D): primary M1 macrophages (C) and M1-THP-1-macrophages (D), and M2 (E and F): primary M2 macrophages (E),
and M2-THP-1 (F) macrophages treated with SKF525A (10 mM). Monocytes were placed in differentiation medium containing vehicle or SKF525A for
7d. M1 and M2-THP-1 cells were identically treated with M1 or M2 differentiation media, however in these experiments, SKF525A (10 mM) was given
to fully differentiated cells at the end of the experiment on day 7 for a further 7 h. The relative TNFa mRNA compared to b-actin levels was measured
by RT-PCR. TNFa release was determined by ELISA. *denotes p,0.05, by one-sample t-test compared to untreated cells.
doi:10.1371/journal.pone.0026591.g006
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however, through the production superoxide anion [9]. In our
experiments TNFa release was suppressed by epoxygenase
inhibition with SKF525A, to the same extent as with removal of
superoxide by the superoxide dismutase MnCl2 [19]. Whether this
is accompanied by a change in anti-inflammatory EET signaling is
not clear. Intriguingly, the M2 phenotype was accompanied by an
induction of CYP2C9 mRNA, the epoxygenase best characterized
as a superoxide generator. SKF525A or IL-4 induced superoxide
generation in THP-1 monocytes, however the combination of
SKF525A and IL-4 showed no increase in superoxide anion
production. These results suggest that IL-4 induces a switch in the
profile of epoxygenase activity to a pro-inflammatory superoxide
generating system. Although IL-4 is generally considered anti-
inflammatory, IL-4 has previously reported to increase as well as
decrease both superoxide anion generation [27,28] and NFkB
activation [29,30] in monocytes depending on the underlying
stimulation.
Our results show an epoxygenase–PPARa axis provides a
critical endogenous break on monocyte/macrophage during
classical activation. This inflammatory breaking signal therefore
represents a novel regulatory mechanism in monocyte/macro-
phages that may regulate disease progression [31,32]. During
alternative activation endogenous epoxygenases limited the anti-
inflammatory activity of IL-4 via superoxide generation, and
potentially by changing the monocyte/macrophage sensitivity to
EETs, highlighting a novel additional immunoregulatory role for
epoxygenases during Th2 mediated immune responses.
Methods
Ethics Statement
Ethics to take blood samples from healthy volunteers were
approved by the St Thomas’s Hospital Research Ethics Commit-
tee (07/Q0702/24), and conducted according to the Declaration
of Helsinki. All volunteers gave written informed consent prior to
entering the study.
Materials
NFkB-luc reporter plasmid was from Clontech (Takara Bio
Europe/Clontech, Saint-Germain-en-Laye, France). Rabbit poly-
clonal anti-CYP2J2 was raised as previously described [33].
pCMXmPPARa and dominant negative DN-(h6/29) hPPARa
were gifts from Dr Ruth Roberts (AstraZeneca; Maccelsfield,
U.K.). EETs and the PGD2 ELISA were from Cayman Chemical
Company (Cambridge Bioscience, Cambridge, UK). SKF525A
was from Biomol (Affiniti Research Products, Exeter, UK).
NovaFECTOR was from VennNova (Pompano Beach, FL,
USA). Dihydroethidium and Dil labelled acetylated-(ac)-LDL
conjugate was from InVitrogen (Paisley, Renfrewshire, UK).
cAMP HTRF assay was from Cisbio (Codolet, France). ECL
reagents, hyperfilm were from GE Healthcare (Little Chalfont,
Buckinghamshire, UK). Cytokines were from R&D Systems
(Abingdon, Oxfordshire, UK). Unless stated, all other reagents
were from Sigma-Aldrich (Poole, Dorset, UK).
Cell and tissue culture
HEK293 (ATCC; LGC Standards, Middlesex, UK) were
cultured in DMEM, and THP-1 were cultured in RPMI
supplemented with antibiotic/antimycotic mix, and 10% FBS;
37uC; 5% CO2; 95% air. Primary monocytes were isolated from
peripheral blood of human volunteers as previously described [34].
Four million cells per well were left to adhere to the culture plastic
for 1.5 hr at which point non-adherent cells were discarded. M1
and M2 differentiation was achieved by stimulation of the adhered
monocytes or PMA treated THP-1 cells with 1 ng/mL LPS (E. coli
serotype 026:B6) and 20 ng/mL IFNc for the M1 phenotype and
20 ng/ml IL-4 for the M2 phenotype for four days. The
concentrations of the cytokines for M1 and M2 differentiations
were selected from two publications [35,36].
Cell morphology, dihydroethidium staining (10 mM for 30 min
at the end of the experiment) [37] and Dil-acLDL uptake (5 mg/ml
for 24–72 h) was analyzed using a Nikon TE2000 inverted
florescent microscope connected to a SPOT-RT digital camera.
The figures shown were created from unmodified images from 2–6
random low magnification fields (x200), analyzed for mean
florescent intensity using ImageJ image analysis software (http://
rsb.info.nih.gov/ij/). The photo-images shown for the purposes of
clarity have been modified in an identical manner in Powerpoint
(contrast and brightness). Luciferase assays were performed as
previously described [38].
RT-PCR
Cell and tissue samples analyzed by RT-PCR were lysed and
RNA isolated using Trizol
TM (Invitrogen). Human b-actin [39]
and COX-2 [40] were as previously described. Human TNF-
alpha gene forward primer 59-CAG AGG GCC TGT ACC TCA
TC-39 and reverse primer 59-GGA AGA CCC CTC CCA GAT
AG-39 producing a 218-bp fragment. DC-SIGN, forward primer:
59-AGT GGG TGA GCT TCC AGA GA-39 and reverse primer
59-CTA AAT TCC GCG CAG TCT TC-39 producing a 405-bp
fragment. CYP2J2, forward primer 59-GCC CGG GAG TCC
ATG CCC TA-39 and reverse primer 59-AAC AGC GCA GAG
GCG GTG AC-39 producing a 435-bp fragment. CYP2C8,
forward primer 59-CGG TGT GCC CCA TGC AGT GA-39and
reverse primer AGA TCG GCA GCC AGA TGG GC-39
producing a 411-bp fragment. CYP2C9, forward primer ATT
GAC CTT CTC CCC ACC AGC-39 and reverse primer GCA
AAT CCA TTG ACA ACT GGA GT producing a 355-bp
fragment. Amplification was performed in a Techgene Techne
TC-312 thermal cycler programmed for an initial denaturation of
5 min at 94uC, followed by 25–35 cycles of 1 min at 94uC, 1 min
at 57–60uC and 2 min at 72uC, and a final extension of 7 min at
72uC. 12 ml of the PCR reaction was subjected to electrophoresis
on 1.5% agarose gel and the products visualized by ethidium
bromide staining. The gel image was captured with a Gel doc
1000 BIORAD digital camera.
Western Blotting, immunoassays, and EET measurements
CYP2J2, COX-2, PPARa, and b-actin protein levels were
measured as previously described [33,38]. CYP2J2 antibody cross-
reacts with CYP2J subfamily enzymes but not other isoforms [33].
The intensity of the bands was digitalized, analyzed and quantified
with the Image J Software Package (NIH). TNFa, PGD2 ELISAs
and cAMP HTRF assays were performed according to manufac-
turer’s instructions. LC/MS/MS analysis of epoxygenase products
in culture supernatants were measured as previously described
[41].
Supporting Information
Figure S1 Epoxygenase inhibition increase macrophage
lipid uptake. SKF525A treatment (10 mM; 72 h) increases the
uptake of DiL-acetylated LDL which is inhibited if co-treated with
the selective PPARa ligand GW7647 (100 nM). Cells were initially
pre-treated with PMA (5 nM) for 24 h. Left panels show
representative micrographs (x400) of ac-LDL uptake, figure shows
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mean 6 SEM of n=4 experiments.
(PDF)
Figure S2 (A & B) shows COX-2 mRNA (C) and TNFa
mRNA (D) relative to b-actin in THP-1 cells treated with
vehicle (Cont), or treated with SKF525A (10 mM), IL-4
(20 ng/ml or IL-4 with SKF525A for 7 h. Data represents
mean 6 SEM of n=4 experiments. * indicates p,0.05; one way
ANOVA compared to control. (C) Intracellular cAMP levels (pg/
ml) are unchanged in THP-1 cells treated with vehicle control
(Cont) or SKF525A (10 mM) for 7 h. (D) Shows the comparison of
inhibition of basal TNFa release from THP-1 cells treated with
1 mM of 11,12-EET or 9,10-EPOME. Data represents mean 6
SEM of n=3 experiments.
(PDF)
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